Stay updated on CAcTUS: ctDNA-Guided Switch Clinical Trial
Sign up to get notified when there's something new on the CAcTUS: ctDNA-Guided Switch Clinical Trial page.

Latest updates to the CAcTUS: ctDNA-Guided Switch Clinical Trial page
- ChecktodayChange DetectedThe CAcTUS study record is now displayed, describing a Phase 2 melanoma trial investigating ctDNA-guided switching between targeted and immune therapies, along with its participation criteria, study plan, and record details.SummaryDifference54%

- Check7 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check14 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check21 days agoChange DetectedThe footer site revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.SummaryDifference0.2%

- Check28 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe study page now displays a 403 Forbidden message instead of the usual study details, indicating restricted access to the record rather than an update to the study information.SummaryDifference19%

Stay in the know with updates to CAcTUS: ctDNA-Guided Switch Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CAcTUS: ctDNA-Guided Switch Clinical Trial page.